Filing Flows › Zenas BioPharma (ZBIO) › Who owns the stock
Who owns Zenas BioPharma (ZBIO) stock
135 funds reported Zenas BioPharma (ZBIO) shares in their latest 13F filings, worth $1.6B in all. The largest holder is FMR LLC ($241M). Last quarter 82 funds added to their stakes and 53 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| FMR LLC | 9,506,701 | $241M | increase | 2026-06-30 |
| SR One Capital Management, LP | 5,037,854 | $128M | unchanged | 2026-06-30 |
| NEA Management Company, LLC | 4,023,219 | $102M | unchanged | 2026-06-30 |
| Enavate Sciences GP, LLC | 3,919,159 | $99.5M | unchanged | 2026-06-30 |
| Federated Hermes | 3,116,805 | $79.1M | decrease | 2026-06-30 |
| BlackRock | 2,686,225 | $68.2M | increase | 2026-06-30 |
| Capital International Investors | 2,502,912 | $63.5M | increase | 2026-06-30 |
| Polar Capital Holdings | 2,412,772 | $61.2M | decrease | 2026-06-30 |
| Royalty Pharma Sub-Manager, LLC | 2,388,150 | $60.6M | unchanged | 2026-06-30 |
| Fairmount Funds Management LLC | 2,359,025 | $59.9M | unchanged | 2026-06-30 |
| Vanguard Group | 1,453,065 | $52.8M | increase | 2025-12-31 |
| State Street | 2,055,100 | $52.2M | increase | 2026-06-30 |
| NVP Associates, LLC | 1,838,482 | $46.7M | unchanged | 2026-06-30 |
| Wellington Management Group LLP | 1,593,819 | $40.5M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 1,354,864 | $34.4M | increase | 2026-06-30 |
Zenas BioPharma's latest quarter
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most ZBIO stock?
By the latest 13F filings: FMR LLC ($241M); SR One Capital Management, LP ($128M); NEA Management Company, LLC ($102M); Enavate Sciences GP, LLC ($99.5M); Federated Hermes ($79.1M).
What is the short interest in ZBIO?
12,538,549 shares were sold short at the 2026-10-15 settlement, 5.0% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.